buy on dips strategy to follow before budget in feb

BIOCON Biocon Limited is an Indian biopharmaceutical company engaged in developing and manufacturing generic formulations, biosimilars, and other biologic medicines. The company operates in a sector that can benefit from increasing demand for affordable healthcare, chronic disease treatments, and advanced biological therapies. Biocon's investment outlook depends on several factors, including business growth, profitability, product launches, regulatory approvals, research and development expenditure, and performance in international markets. Biocon reported consolidated operating revenue of ₹4,336 crore in Q1 FY2026–27, up 10% year-on-year. EBITDA stood at ₹902 crore, while reported net profit was ₹141 crore. Biosimilars revenue grew 16% and generics revenue increased 21%, whereas services revenue declined 16%. These figures indicate that the biopharma business is contributing to growth, but weakness in services remains an area to monitor. Investors should also evaluate debt, interest expenses, cash flow, integration costs and sustainable earnings before making a long-term investment decision. Based on recent price action through 26 October 2026, the following are indicative chart-based zones, not guaranteed price targets. Level Price zone Significance Immediate support ₹321–318 Recent swing-low area Next support ₹310–300 Potential downside zone Stronger lower zone ₹290–285 Further weakness scenario Immediate resistance ₹330–335 Near-term selling zone Next resistance ₹349–355 Previous price congestion Major resistance ₹370–375 Earlier breakdown area The recent trading history shows that the stock declined from around ₹395 on 23 September to ₹328.80 on 26 October. The recent low near ₹318.50 is therefore an important level to watch.